SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-22-083675
Filing Date
2022-07-28
Accepted
2022-07-28 16:30:19
Documents
4

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2222011d1_defa14a.htm DEFA14A 14520
2 GRAPHIC tm2222011d1_defa14aimg001.jpg GRAPHIC 4691
3 GRAPHIC tm2222011d1_defa14aimg002.jpg GRAPHIC 2041
4 GRAPHIC tm2222011d1_defa14aimg003.jpg GRAPHIC 32766
  Complete submission text file 0001104659-22-083675.txt   70699
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38356 | Film No.: 221115619
SIC: 2834 Pharmaceutical Preparations